Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

By Lundkvist Jonas   Wilking Nils   Holmberg Stig   Jönsson Linus  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 289-299

Springer Publishing Company

Access to resources Recommend Favorite

Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

By Cella David   Fallowfield Lesley   Barker Peter   Cuzick Jack   Locker Gershon   Howell Anthony  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 273-284

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: Is it cost-effective?

By Norum Jan   Holtmon Mari  

Acta Oncologica, Vol. 44, Iss. 7, 2005-10 ,pp. : 735-741

Informa Healthcare

Access to resources Recommend Favorite

Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

By Skedgel C.   Rayson D.   Dewar R.   Younis T.  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 325-333

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effective analyses in Breast Cancer Research and Treatment

By Lippman Marc  

Breast Cancer Research and Treatment, Vol. 115, Iss. 2, 2009-05 ,pp. : 221-222

Springer Publishing Company

Access to resources Recommend Favorite